World’s First clinical trial for DMT-assisted therapy in Major Depressive Disorder Shows Consistent Quality of… Feb 22, 2022
Cybin Announces Grant of U.S. Patent Covering its Proprietary Compound CYB004 (Deuterated DMT) for the Treatment of… Feb 9, 2022
Entheon Biomedical: Could DMT Be A Superior Psychedelic Treatment For Substance Use Disorder? Feb 4, 2022
Psygen Receives Dealer’s Licence To Become Canada’s First Dedicated Psychedelics Manufacturing Facility Jan 18, 2022
Cybin Awarded Notice of Allowance from U.S. Patent and Trademark Office for CYB004 (Deuterated Psychedelic Tryptamine)… Dec 15, 2021
